News | November 01, 2024
Supriya Lifescience reports 19% revenue increase in Q2 FY25
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
he company will focus on production of any pharmaceutical and biotechnological products
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Subscribe To Our Newsletter & Stay Updated
